Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.74 |
| ▸ | DRD2 | P14416 | 4/20 | 0.74 |
| ▸ | HTR2A | P28223 | 4/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.74 |
| ▸ | DRD1 | P21728 | 1/20 | 0.74 |
| ▸ | DRD4 | P21917 | 1/20 | 0.74 |
| ▸ | ACHE | P22303 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | HTR2C | P28335 | 1/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.74 |
| ▸ | CCKBR | P32239 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | HRH1 | P35367 | 1/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.74 |
| ▸ | DRD3 | P35462 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1566550 | 1.00 | HTR1A (0.74) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| SCHEMBL1566323 | 1.00 | HTR1A (0.74) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| SCHEMBL30620874 | 1.00 | HTR1A (0.74) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| SCHEMBL8825541 | 0.97 | HTR1A (0.69) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| SCHEMBL114490 | 0.93 | HTR1A (0.74) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| SCHEMBL10006696 | 0.91 | HTR1A (0.76) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| SCHEMBL8883603 | 0.91 | HTR1A (0.65) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| SCHEMBL1545992 | 0.91 | ABCB11 (0.64) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| SCHEMBL16027132 | 0.90 | HTR1A (0.71) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| SCHEMBL6025000 | 0.90 | HTR1A (0.69) | HTR1ADRD2HTR2AABCB11CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544367-B2 | Method of treatment of schizophrenia | VANDA PHARMACEUTICALS INC. (US) | 2026-02-10 | — | — | US | claimed |
| US-10570452-B2 | Method of predicting a predisposition to QT prolongation | VANDA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | claimed |
| US-10563261-B2 | Method of predicting a predisposition to QT prolongation | VANDA PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | claimed |
| US-10563260-B2 | Method of predicting a predisposition to QT prolongation | VANDA PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | claimed |
| EP-3354753-B1 | METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE | VANDA PHARMACEUTICALS INC (US) | 2020-02-12 | — | — | EP | claimed |
| EP-3345603-B1 | ILOPERIDONE METABOLITE FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | VANDA PHARMACEUTICALS INC (US) | 2019-12-18 | — | — | EP | claimed |
| EP-3492081-A1 | METHODS FOR THE ADMINISTRATION OF ILOPERIDONE | Vanda Pharmaceuticals Inc. (US) | 2019-06-05 | — | — | EP | claimed |
| EP-2331098-B1 | METHODS FOR THE ADMINISTRATION OF ILOPERIDONE | VANDA PHARMACEUTICALS INC (US) | 2018-08-08 | — | — | EP | claimed |
| EP-3354753-A1 | METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE | Vanda Pharmaceuticals Inc. (US) | 2018-08-01 | — | — | EP | claimed |
| EP-3023506-B1 | METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE | VANDA PHARMACEUTICALS INC (US) | 2018-03-14 | — | — | EP | claimed |
| WO-2010117943-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION BASED ON BAI3 GENE SEQUENCE OR PRODUCT THEREOF | VANDA PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | claimed |
| WO-2010117937-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | VANDA PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | claimed |
| US-20100226858-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | VANDA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | claimed |
| EP-2134873-A2 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | Vanda Pharmaceuticals Inc. (US) | 2009-12-23 | — | — | EP | claimed |
| WO-2008121899-A2 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | VANDA PHARMACEUTICALS INC. (US) | 2008-10-09 | — | — | WO | claimed |
| US-RE39198-E1 | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics | AVENTIS PHARMACEUTICALS INC. (US) | 2006-07-18 | — | — | US | claimed |
| US-5364866-A | Side effect reduction | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1994-11-15 | — | — | US | claimed |
| EP-0612318-A1 | HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-08-31 | — | — | EP | claimed |
| EP-0542136-A1 | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-05-19 | — | — | EP | claimed |
| WO-1993009102-A1 | HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1993-05-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544367-B2 | Method of treatment of schizophrenia | ILF2, NPFFR2, GTF2F2 | HTR1A 624/4885DRD2 54/4885HTR2A 100/4885 |
| US-10563261-B2 | Method of predicting a predisposition to QT prolongation | SLC47A2, ABCC2, SLC47A1 | HTR1A 1408/4885DRD2 3297/4885HTR2A 1004/4885 |
| US-20100226858-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | CERS2, CERT1, SPTLC1 | HTR1A 4129/4885DRD2 4539/4885HTR2A 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.